February 28 - March 2, 2025
Day 1
It is anticipated that the new LCDs will limit reimbursement of CAMPs for diabetic
foot ulcers and venous leg ulcers to those with a strong evidence base, and then for
up to four applications only, unless a clinical case can be made for longer term use.
This will have implications for both patients and health-care providers. This session
will outline what it means for you.
Use of more than four applications of CAMPs is only likely to be permitted by the
forthcoming the LCDs for diabetic foot ulcers and venous leg ulcers if certain clinical
criteria are met. This session will advise on how to justify this using the Kx modifier.
Only access to CAMPs with a robust evidence base will be allowed by the new LCDs.
But the evidence base for many CAMPs is highly variable, and is not necessarily an
indication of their efficacy and cost-effectiveness. In this session, a panel will debate
the minimum evidence requirements for all CAMPs going forward.
There are fears that the pending restrictions to reimbursement will extend to a
broader range of indications such as tunnels, post-Mohs and even pressure ulcers,
depriving patients of much-needed access. This session will survey the published and
experiential evidence on the efficacy of CAMPs on these wound types, and propose
how to preserve access to them.
In honour of the late and much-missed Dr Gregory Schultz, this presentation will describe
how this Program will support up-and-coming CAMPs providers, to help them reach
their full potential and move the discipline forward.
Use of CAMPs on diabetic foot ulcers is well established, with a growing evidence
base on its clinical efficacy and cost-effectiveness. This session will outline the latest
research findings, which give real insight into accelerated healing rates and cost
savings that can be achieved with this technology.
Recent research is making a strong case for the clinical and economic benefits of
using CAMPs on venous leg ulcers. This talk will explore the latest evidence for this
indication, pointing to the real difference these advanced products can make to
patient outcomes.
Option 1: Effective debridement and wound bed preparation
• Assessment
• Wound bed preparation
• Debridement
• Application
• Updating the wound and ulcer care LCD (L38902)
To facilitate wound healing with CAMPs, all elements of best practice must be
implemented, starting with an in-depth assessment, followed by thorough wound
bed preparation and suitable application. This will ensure a holistic and evidencebased approach, with the right CAMP selected for the patient and applied in the most
effective way. This session will offer practical information on how to achieve this.
Option 2: Technical innovation in assessment of
vascular status and bioburden
• New technology, including clinical imaging, near infra-red spectroscopy
• Fluorescence imaging update, pH detectors
• Portable devices
Many innovative technologies have the potential to transform assessment. For
example, by providing more accurate and precise imagery of vascular perfusion,
bacterial bioburden or the pH level, specialist equipment can identify when initiation
of CAMPs is most likely to be effective and faster healing achieved.
Industry and healthcare providers are in a symbiotic relationship, with wound-care
providers providing feedback and direction for industry, and companies producing
the technical innovations that enable physicians to achieve better patient outcomes.
In this open-forum debate, representatives from health care and industry will discuss
how the two parties can support each other more to mutual advantage.
In this session, a panel of clinical experts will present a selection of case studies
on the use of CAMPs on complex wounds. In an open discussion, attendees and
presenters will explore options and approaches to the care of each wound.
Location: The Westin Fort Lauderdale Beach Resort
Dress code: Smart Casual